Business
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
Raised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG). Completed commercial
About this update from Alpha Cognition Inc.
[{"type":"text","content":"\n\n Raised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG).\n\n\nCompleted commercial manufacturing to support the ZUNVEYL launch.\n\n\nSuccessfully completed the first phase of a pre-clinical bomb-blast study funded by a Department of Defense grant, demonstrating benzgalantamine’s efficacy and safety in treating head trauma from simulated bomb blasts.\n\n\nCash and cash equivalents of $48.6 million as of December 31, 2024, compared to $3.7 million as of September 30, 2024 and $1.4 million as of December 31, 2023. At current cash utilization rates, the Company expects a cash runway of approximately two years.\n\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAlpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”) today announced its financial results for the fourth quarter and full year ended December 31, 2024.\n\n“We closed 2024 on a strong note, securing capital to support the ZUNVEYL commercial launch and assembling an experienced leadership team,” said Michael McFadden, Chief Executive Officer. “In early 2025, we completed the manufacturing of the initial commercial supply of ZUNVEYL. Additionally, we’ve invested in commercial infrastructure, product supply, and operational capabilities to support the launch. We introduced ZUNVEYL to the U.S. market in March 2025 and are focused on commercialization excellence.”\n\nRecent Business and Operational Highlights:\n\nCommercial Readiness:\n\nAlpha Cognition successfully hired its commercialization team on schedule and within budget.\n\n\nThe commercial leadership team brings over 100 years of experience in long-term care and CNS and has led 140 product launches.\n\n\nCollectively, our salesforce has an average tenure of 16 years industry sales experience and 10 years in long-term care.\n\n\nThe Company launched its commercialization efforts in the U.S. in March 2025, making ZUNVEYL available to physicians and patients.\n\n\nStrategic Global Expansion:\n\nIn January 2025, Alpha Cognition signed its first ex-U.S. distribution deal for ZUNVEYL with China Medical System Holdings Limited (CMS) (867.HK), a leading pharmaceutical platform company with strong commercialization and product lifecycle management expertise in the People’s Republic of China.\n\n\nThe deal is valued at $44 mi...